Sonomind is a medical device company developing a non-invasive neuromodulation therapy based on low-intensity focused ultrasound for the treatment of depression. The company’s approach is grounded in more than 25 years of academic research into transcranial ultrasound stimulation of deep brain structures involved in mood regulation.

Its technology delivers precision ultrasound stimulation using a patient-specific acoustic meta-lens designed to compensate for skull-induced distortions. This enables millimetric targeting of deep brain regions while maintaining a non-invasive and portable treatment profile. The platform is supported by patented software and know-how licensed exclusively from INSERM.

Sonomind’s system is being developed for clinical use in patients with drug-resistant depression, with potential extension to other neurological and psychiatric conditions. The company positions its technology as a rapid, safe, and targeted neuromodulation therapy that expands treatment options beyond pharmacological and invasive interventions.